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S U M M A R Y
Background: Hepatitis C virus (HCV) is a causative agent of chronic liver disease, cirrhosis, and
hepatocellular carcinoma. In Pakistan, more than 10 million people are living with HCV. Very little is
known about the genotype distribution in Punjab Province, the largest province of Pakistan.
Pretreatment genotype identiﬁcation is very important, as different HCV genotypes respond differently
to interferon therapy.
Methods: In this study we performed HCV genotyping for 1537 HCV-infected patients from different
districts of Punjab Province, Pakistan. Sequencing of partial HCV NS5B sequences from 14 samples
belonging to genotypes 3 and 1 was also done. A sequence comparison was made of our reported
sequences with those reported in the National Center for Biotechnology Information (NCBI), and a
phylogenetic tree was constructed.
Results: Our study showed that the most frequent HCV genotype was 3a (in 88.1% of infected
individuals), followed by 1a (3.5%), 3b (3.0%), 1b (0.8%), and 2a (1.0%). A mixed genotype infection was
found in 3.6% of infected individuals, with 0.3% living with 1a + 1b co-infection, 3.1% with 3a + 3b, and
0.2% suffering from 3a + 1b co-infection. The sequence comparison showed that HCV NS5B motif B
residues G283, T287, and N291 were highly conserved in both genotype 1 and genotype 3 sequences,
while the motif B residue T286 was mutated to proline in all the genotype 3 sequences. The GDD motif,
which forms the catalytic pocket and binding site for the divalent cations, was highly conserved in all the
reported sequences. The phylogenetic tree suggests clustering of genotype 1 sequences with sequences
from the USA, UK, Germany, and France, while genotype 3 sequences are clustered with sequences from
Japan and the UK.
Conclusions: The major prevalent genotype in Punjab Province of Pakistan was genotype 3a, followed by
genotype 1a, and only 3.6% of infected individuals had a mixed genotype infection. Sequencing of the
HCV NS5B gene suggested that the active site residues were highly conserved in all the reported
sequences. Our sequences, which are clustered with sequences from the USA, UK, France, and Japan,
show the diversity in origin of the different genotypes prevalent in Pakistan.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis C virus (HCV) constitutes a major public health issue
around the world in general, and in Pakistan in particular.1 About
200 million people are infected with HCV worldwide, which covers
about 3.3% of the world’s population.2,3 In the Asia-Paciﬁc region,
the prevalence of HCV infection ranges from 0.3% to 12%,4 and in
Pakistan more than 10 million people are living with HCV.5* Corresponding author.
E-mail address: hafsa.aziz@gmail.com (H. Aziz).
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http://dx.doi.org/10.1016/j.ijid.2012.09.017Available data from the Pakistani population reveal that the
prevalence of hepatitis C is 4–6%,6 while a community-based study
in Karachi revealed a hepatitis C prevalence of 6.6% and a study in
Punjab (Haﬁzabad) reported a prevalence of 6.5%.7,8 Government
agencies acknowledge that the overall prevalence of hepatitis C in
the general Pakistani population is 5.3%.9
HCV isolates show nucleotide sequence variability throughout
the viral genome and this has consequences for the effectiveness of
treatment. The nucleotide sequence variability of HCV is probably
related to replication errors by the RNA-dependent RNA polymer-
ase.10,11 Each HCV genotype and subtype is distributed differently
in different parts of the world, and certain genotypes predominateses. Published by Elsevier Ltd. All rights reserved.
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the world. The most abundant subtype in South America, Europe,
and Australia is HCV subtype 1a, while subtype 1b is found in North
America and Europe and is also found in parts of Asia.12,13
The response to interferon therapy is related to the HCV
genotype. Therefore knowledge about the diversity of HCV may
have important implications for prognosis and therapy. Using
multivariate analysis, Tsubota et al. concluded that HCV genotype
1b was an independent predictor of a poor response to interferon
therapy when compared to genotypes 2 and 3.14 In another study
we found 76% of genotype 3 patients to have a sustained virological
response (SVR) compared to 55% of genotype 1 patients.1
Few studies have attempted to determine the overall distribu-
tion of HCV genotypes in Pakistan. The distribution of HCV
genotypes in the different geographical divisions of Punjab is
unknown. We know that knowledge of the HCV genotype is of
prime importance in the clinical management of HCV. In this
regard, less frequent genotypes deserve the same attention as the
more common genotypes. Therefore this research was planned to
determine the geographic distribution of HCV genotypes in the
different geographical divisions of Punjab Province, Pakistan. We
also sought to perform a sequence comparison and phylogenetic
analysis of the dominant genotypes.
2. Materials and methods
2.1. Patient selection and study design
Human HCV-positive blood samples from 1537 HCV-infected
patients were collected from hospitals of the different divisions of
Punjab: 569 from Lahore, 340 from Rawalpindi, 150 from
Sargodha, 100 from Gujranwala, 150 from Dera Ghazi Khan,
Multan, and Bahawalpur, and 228 from Faisalabad. Eligible
patients were male and female, aged >18 years, with a
documented chronic HCV infection according to the following
criteria: patient positive for anti-HCV antibody by Abbott Architect
Anti-HCV assay and with a positive PCR for HCV RNA. None of the
patients selected for the study had started antiviral therapy, and
none were habitual alcohol or active intravenous drug users.
This study was conducted at the Nuclear Medicine Oncology
and Radiotherapy Institute of Islamabad from June 2010 through
November 2011. All patients signed a form containing their
demographic information. This form was approved by the ethics
committee of the institute. Written informed consent was also
obtained from all the patients who participated in this study. Anti-
HCV antibody-positive patients were screened for HCV RNA using a
commercial kit and a real-time PCR. Patients who were negative for
HCV RNA were excluded.
2.2. HCV RNA extraction and detection
Plasma was isolated and the extraction of RNA was carried out
with an INSTANT Virus RNA Kit (AJ Roboscreen, GmbH, Leipzig,
Germany) in accordance with the manufacturer’s protocol. The
HCV viral load was determined using a RoboGene HCV RNA
Quantiﬁcation Kit (AJ Roboscreen) on a real-time PCR instrument
(RotorGene 3000; Corbett Research, Sydney, Australia).
2.3. HCV genotyping
Samples from HCV patients were subjected to genotyping based
on HCV core region-speciﬁc primers, using the method of Ohno
et al., with some modiﬁcations.15 RNA was reverse-transcribed
into cDNA using an antisense primer of the core region. Brieﬂy,
10 ml of extracted RNA was mixed with 10 ml of Master Mix
containing 4 ml of 5 reaction buffer, 2 ml dNTPs mix (10 mmol/leach), 25 pmol antisense external primer, 40 U of RNAse inhibitor
(Fermentas, Canada), and 200 U of Moloney murine leukemia virus
reverse transcriptase (Fermentas) and incubated for 1 h at 42 8C,
followed by 2 min at 90 8C.
PCR ampliﬁcation was performed in a 20 ml volume containing
10 ml of Green Go Taq Master Mix (Promega, USA), 25 pmol of each
outside sense and outside antisense primer, and 4 ml of cDNA and
subjected to the ﬁrst round of PCR for 20 cycles at 94 8C for 1 min,
45 8C for 1 min, and 72 8C for 1 min, and 20 cycles at 94 8C for
1 min, 60 8C for 1 min, and 72 8C for 1 min, as reported by Ohno
et al.15 The second round PCR reaction was performed in two
separate mixtures with genotype-speciﬁc primers. The PCR
product was analyzed on 2% agarose gel.
2.4. Partial sequencing of the HCV NS5B region
Partial NS5B (nucleotides 688–978) sequencing was performed
and used to validate our HCV genotyping results. To amplify DNA
fragments to be sequenced from the NS5B region, a single primer
pair considered to be highly conserved amongst the different
variants of HCV was used. A 50 ml volume containing 25 ml of
Green Go Taq Master Mix (Promega), 1.25 pmol of each outside
sense (GACACCCGCTGTTTTGACTC) and outside antisense
(TTCACGGAGGCTATGACCAGGTA) primer, and 5 ml of cDNA as
template was used for the PCR ampliﬁcation. The ampliﬁcation
conditions were: 5 min at 94 8C, followed by 35 cycles each
consisting of 95 8C for 30 s, 68 8C for 45 s, and 72 8C for 60 s, in a
GeneAmp PCR System 9700 (Applied Biosystems). The PCR product
was analyzed on 2% agarose gel. The PCR product was puriﬁed from
the gel using the PureLinkTM Quick Gel Extraction Kit (Invitrogen)
in accordance with the manufacturer’s protocol. Puriﬁed samples
of selected genotypes were subjected to sequencing using an ABI
Automated Sequencer (Applied Biosystems). The nucleotide
sequences were viewed using Chromas version 2.0. Electropher-
ograms of each sample were analyzed and ambiguities in the
sequence data were solved by comparison of the results of both
forward and reverse primers. These sequences were aligned using
CLC Workbench software (http://www.clcbio.com) to draw a
consensus sequence. The consensus sequences have been submit-
ted to the National Center for Biotechnology Information (NCBI).
Fourteen representative NS5B gene sequences of HCV from this
study and 24 sequences of HCV genotypes 1 and 3 retrieved from
the NCBI nucleotide databank were used for the construction of a
phylogenetic tree. The phylogenetic tree was constructed using
CLC Workbench and the neighbor-joining method.16
3. Results
In this study we performed the molecular genotyping of 1537
HCV samples from Punjab Province, Pakistan, followed by
genotype conﬁrmation by sequencing of a few samples. We found
that surgery and dental treatments were the main modes of
acquiring HCV, however almost a third of patients did not know the
source of their infection. The characteristics of the HCV patients are
summarized in Table 1.
Serum samples from these HCV patients were subjected to
genotyping based on HCV core region-speciﬁc primers, by the
method of Ohno et al., with some modiﬁcations.15 This method is
very effective and is able to type all HCV-positive plasma samples.
Genotypes 3a, 3b, 2a, 2b, 1a, and 1b were detected, and in some
cases a mixed infection with more than one genotype was also
seen. The predominant genotypes were 3a and 3b followed by 1a,
HCV genotype 2 was found less frequently.
The speciﬁcity of the test was evaluated by testing HCV
serologically negative plasma samples. The genotype primers were
found to be speciﬁc, they gave no false-positive results and showed
Table 1







Surgery + transfusion 220 (14.3%)
Transfusion 131 (8.5%)
Dental treatment 511 (33.2%)






HCV RNA level IU/ml
<100 000 85 (5.5%)
100 000–500 000 276 (18.0%)
>500 000–1 000 000 303 (19.7%)
>1 000 000 873 (56.8%)
Serum ALT levelsa
Normal ALT 346 (22.5%)
Raised ALT 1191 (77.5%)
ALT, alanine aminotransferase; ULN, upper limit of the normal range.
a Raised ALT: patients with serum ALT ULN, i.e., male 41 U/l, female 31 U/l;
normal ALT: patients with serum ALT <ULN, i.e. male <41 U/l, female <31 U/l.
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determination and also 100% reproducibility. The genotypes were
conﬁrmed by sequencing of the HCV NS5B gene, which is
considered the gold standard for genotyping.
3.1. Prevalence of HCV genotypes in Punjab
To investigate the burden of HCV genotypes in HCV-positive
patients in Punjab, a total of 1537 HCV-positive patient samples
were screened for HCV genotyping analysis. Six hundred and sixty-
seven patients were male and 870 were female, and their mean age
was 41.90  10.66 years. The distribution of HCV genotypes in the
province of Punjab is shown in Figure 1. The most frequent genotype
was 3a (88.1%), followed by 1a (3.5%), 3b (3.0%), 1b (0.8%), 2a (1.0%),
1a + 1b (0.3%), 3a + 3b (3.1%), and 3a + 1b (0.2%). The distribution of
the HCV genotypes varied in the different divisions of the province.Figure 1. Distribution of HCV ge3.2. Distribution of HCV genotypes by geographical area of Punjab
Province
3.2.1. Rawalpindi Division
Three hundred and forty HCV-positive patients, 135 male
(39.7%) and 205 female (60.3%), with a mean age of 42.44  10.38
years were screened for HCV genotype. The most commonly detected
genotype in Rawalpindi Division was genotype 3 (n = 318, 93.5%),
with predominant subtype 3a (n = 304, 89.4%), 3a + 3b (n = 12, 3.5%),
and 3b (n = 2, 0.6%). Genotype 1 (n = 19, 5.6%) comprised the subtypes
1a (n = 12, 3.5%), 1b (n = 5, 1.5%), and 1a + 1b (n = 2, 0.6%). Mixed
genotype 3a + 1b was found in 0.3% of patients (Table 2).
3.2.2. Sargodha Division
Of 150 HCV-infected individuals from Sargodha Division, 88
(58.7%) were male and 62 (41.3%) were female. Their mean age was
39.69  10.33 years. Table 2 shows that 140 (93.3%) had genotype 3a,
while six (4.0%) had genotype 1a. A mixed infection of genotype 3
subtypes, i.e., 3a + 3b, was observed in four (2.7%) patients.
3.2.3. Gujranwala Division
One hundred blood samples were collected from HCV-infected
individuals in Gujranwala Division and screened for HCV genotype.
Only genotype 3a was found; no other genotype was detected in
blood samples from this division.
3.2.4. Dera Ghazi Khan, Multan, and Bahawalpur
The HCV genotype distribution was evaluated in 150 subjects in
this division. HCV genotyping showed that HCV genotype 3a was
most prevalent, found in 87.3%; 12 patients (8.0%) were infected
with genotype 3b and seven (4.7%) had a mixed infection with
genotypes 3a + 3b (Table 2).
3.2.5. Lahore Division
Five hundred and sixty-nine HCV-positive samples were
collected for HCV genotyping from Lahore Division; 236 (41.5%)
were from male patients and 333 (58.5%) from female patients. The
mean age of the patients was 41.79  10.61 years. Genotype 3a was
predominant, found in 461 (81.0%), followed by 3b in 30 (5.3%), 1a in
33 (5.8%), and 1b in ﬁve (0.9%). A mixed genotype 3a + 3b infection
was observed in 25 (4.4%), of 3a + 1b in two (0.4%), and of 1a + 1b in
two (0.4%) (Table 2).notypes in Punjab Province.
Table 2
Distribution of HCV genotypes in different divisions of Punjab
Divisions of Punjab HCV genotype
3a 3b 1a 1b 2a 3a + 3b 3a + 1b 1a + 1b
Lahore 461 (81.0%) 30 (5.3%) 33 (5.8%) 5 (0.9%) 11 (1.9%) 25 (4.4%) 2 (0.4%) 2 (0.4%)
Rawalpindi 304 (89.4%) 2 (0.6%) 12 (3.5%) 5 (1.5%) 2 (0.6%) 12 (3.5%) 1 (0.3%) 2 (0.6%)
Faisalabad 218 (95.6%) 2 (0.9%) 3 (1.3%) 3 (1.3%) 2 (0.9%)
Sargodha 140 (93.3%) 6 (4%) 4 (2.7%)
Dera Ghazi Khan, Multan, and Bahawalpur 131 (87.3%) 12 (8%) 7 (4.7%)
Gujranwala 100 (100%)
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HCV genotype 3a was found to be most prevalent in the 228
HCV samples (95.6%), followed by genotype 1a (1.3%), 1b (1.3%), 2a
(0.9%), and 3b (0.9%) (Table 2).
3.3. Phylogenetic analysis and sequence comparison
These results were further conﬁrmed through phylogenetic
analysis by constructing a phylogenetic tree using the NS5B gene
sequence as a phylogenetic marker. Fourteen HCV NS5B gene
sequences reported in this study, along with 24 sequences obtained
from NCBI belonging to different HCV genotypes were used for the
construction of the phylogenetic tree. HCV NS5B sequences reported
in this study have been submitted to NCBI and have been assigned the
following accession numbers: NORI\PU-2 (HQ661847.1), NORI\PU-5
(HQ661850.1), NORI\PU-6 (HQ661851.1), NORI\PU-7 (HQ661852.1),
NORI\PU-8 (HQ661853.1), NORI\PU-9 (HQ661854.1), NORI\PU-12
(HQ661857.1), NORI\PU-10 (HQ661855.1), NORI-HCV-14 (JQ95Figure 2. Phylogenetic tree of the NS5B gene of HCV showing the relationship of the 13 p
strains isolated from chronic HCV patients reported in this study, with sequences from t
Workbench software.7850.1), NORI-HCV-15 (JQ957851.1), NORI-HCV-16 (JQ957852.1),
NORI-HCV-17 (JQ957853.1), NORI-HCV-18 (JQ957854.1).
Our reported genotype 1a sequences are clustered with
sequences from the USA, UK, and Germany, while our 1b sequences
are clustered with sequences from Japan, France, and Germany.
The genotype 3b sequences are clustered with 3b sequences from
Japan, while genotype 3a sequences are clustered with sequences
from the UK and Japan, as shown in the phylogenetic tree in
Figure 2.
The genotype 3 and 1 sequences reported in this study were
aligned with genotype 3 (NzL, K3a) and genotype 1 (H77)
sequences taken from NCBI. Our reported HCV NS5B sequences
were from the HCV NS5B gene, amino acids 229 to 326. The
sequence comparison suggests that the HCV NS5B gene residues
that form the motif B – G283, T287, and N291 – are highly
conserved in both genotype 1 and genotype 3 sequences, while the
motif B residue T286 is mutated to proline in all the genotype 3
sequences. The GDD motif which forms the catalytic pocket for theartial NS5B nucleotide sequences in representative HCV subtype 1a, 1b, 3a, and 3b
he NCBI having different genotypes and origins. The tree was constructed using CLC
Figure 3. Comparison of amino acid sequence alignment in the NS5B region (292 bp) (position 8212–8510).
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sequences, as shown in Figure 3.
4. Discussion
Knowledge of HCV genotype has gained importance because it
has a role in elucidating the therapeutic, prognostic, and the
clinical status of the HCV infection. Several clinical trials have
found that the HCV genotype is strongly associated with the
response to combination therapy,17 and the pathogenesis of the
disease also varies according to the type of virus. Hence
pretreatment determination of HCV genotype helps in determining
the suitability of the treatment regimen and duration.18 Further-
more, epidemiological patterns of HCV genotype vary in different
geographical areas, even among regions of the same country.
However, little is known about the epidemiology of HCV genotypes
in Punjab Province of Pakistan. Therefore this study was carried out
to gain an understanding of the prevalence of the various
genotypes among the different divisions of Punjab Province; this
will help to guide the therapeutic choices and identify the
prognostic implications of HCV infection in Punjab.The results of
the present study indicated that the predominant HCV genotype in
infected patients of Punjab Province was subtype 3a, with a
prevalence rate of 88.1%. This ﬁnding is in accordance with those of
different studies conducted in different parts of Pakistan.19 In a
study carried out by Idrees and Riazuddin on 3351 HCV-infected
patients, 1664 (49.7%) patients had genotype 3a, 592 (17.7%) had
genotype 3b, 280 (8.4%) had genotype 1a, 252 (7.5%) had genotype
2a, 101 (3.0%) had genotype 1b, and 50 (1.5%) had genotype 4.20 In
another study from the Pakistan Medical and Research Council,
79.5% (17l/275) of HCV patients were reported to have a genotype
3 infection.21 Genotype 3 is also the most prevalent genotype in
India, Nepal, and Bangladesh.22–24
Our study reports a high prevalence of HCV genotype 3 in the
different divisions of Punjab, as shown in Figure 1. Our results are
similar to those of Shah et al., who reported an 87% prevalence of
genotype 3, and with the consensus statement on HCV genotypes
reported by a team of gastroenterologists, who reported a 75–90%
prevalence of genotype 3 in Pakistan.6,25 The phylogenetic analysis
of our reported HCV 3a and 3b genotype sequences showed
clustering with genotype 3a and 3b sequences reported from
Japan; this observation is in accordance with a previously reported
phylogenetic analysis of HCV core sequences by Waheed et al.5
The second most frequent HCV genotype reported in our study
was genotype 1. Our data are in agreement with the largest report
of HCV genotypes from Pakistan, reported by Idrees and Riazuddin
in 2008, stating that the second most prevalent HCV genotype in
Pakistan is genotype 1.20 The phylogenetic analysis of HCV
genotypes from Pakistan suggests that the different HCV geno-
types evolved from genotype 1a. These data are in agreement with
the analysis of HCV polymerase sequences by Waheed et al.
(unpublished data), while Sarwar et al. reported the evolution of
different HCV genotypes from genotype 1b.26 The phylogenetic
analysis shown in Figure 2 suggests that the Pakistani subtype 1a
sequences are clustered with 1a sequences from the USA and
Germany, while subtype 1b sequences are clustered with
sequences from Germany and France; these sequences might
have some evolutionary relationship.
We found genotype 2 in plasma samples of infected individuals
from Faisalabad, Lahore, and Rawalpindi divisions. This genotype is
uncommon in Pakistan, although this ﬁnding is not surprising in
light of the fact that studies from the neighboring country India
have also reported a low level incidence of HCV genotype 2.22 The
lower prevalence rates of other genotypes may be explained as
sporadic cases of transmission of genotypes from other geographi-
cal regions in which the endemicity of these genotypes is higher.Another important ﬁnding is the observation of the absence of
genotype 4 in all studied divisions of Punjab. We think that this
may be due to the rare occurrence of genotype 4 in neighboring
countries like Iran.27
In the current study, mixed genotype infections were found in
55 (3.6%) of the HCV-infected individuals. This information
suggests that a person suffering from one HCV genotype is also
at risk of acquiring infection with another genotype. The frequency
of individuals suffering from mixed infections is comparable to
that reported by Idrees and Riazuddin,20 who found a 4.8%
prevalence of mixed HCV genotype infections in Pakistan. In
another report by Butt et al.,28 mixed genotype distribution
occurred in decreasing order of 3a + 3b, 3a + 1b, 1a + 1b, etc., but in
our study we found small mixed genotype samples in the
decreasing order of 3a + 3b,1a + 1b, 3a + 1b. The difference in the
order of mixed genotypes may be due to regional differences, the
use of different assays for genotyping, or sample size differences.
The sequence comparison showed that the HCV NS5B motif B
residues G283, T287, and N291 were highly conserved in both
genotype 1 and genotype 3 sequences, while the motif B residue
T286 was mutated to proline in all the genotype 3 sequences. The
GDD motif, which forms the catalytic pocket and binding site for
the divalent cations, was highly conserved in all the reported
sequences suggesting the great importance of these structures in
its function.29,30
In conclusion, the use of core region genotype-speciﬁc primers
and sequence analysis of the NS5B gene of HCV for genotype
identiﬁcation provided an accurate epidemiological picture of the
circulating viral strains in Punjab Province, Pakistan. The most
prevalent genotype was 3, followed by genotype 1. Our reported
genotype 1 sequences have high homology with sequences
reported from the USA, Germany, and France, while our genotype
3 sequences have high homology with sequences reported from
Japan. Pretreatment genotype determination is very important, as
infections with genotype 3a have a rapid response to therapeutic
regimens and this may be used as a marker for a short duration of
therapy, thereby decreasing the economic burden on the country.
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